Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage Breast Cancer

NCT05333874 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT05333874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05333874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage Breast Cancer
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 6, 2022
Completion date
November 28, 2027
Enrollment
34 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early-onset